mRNA-1273 vaccine induces anti-SARS-CoV-2 immune responses
24 Jul 2020
byElaine Soliven
Two doses of mRNA-1273, a novel lipid nanoparticle-encapsulated, nucleoside-modified mRNA-based vaccine, induced binding and neutralizing antibody responses against SARS-CoV-2 in healthy adults, according to an interim analysis of the mRNA-1273* trial.